104 related articles for article (PubMed ID: 1485373)
1. A radioimmunoassay for the new antiviral agent 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Jagoda E; Ogan M; Stouffer B; Tsay HM; Turabi N; Mantha S; Yost F; Tu JI
Ther Drug Monit; 1992 Dec; 14(6):499-508. PubMed ID: 1485373
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.
Ashida N; Ijichi K; Watanabe Y; Machida H
Biochem Pharmacol; 1993 Dec; 46(12):2201-7. PubMed ID: 8274153
[TBL] [Abstract][Full Text] [Related]
3. Retinal toxicity and ocular kinetics of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rabbits.
Mochizuki K; Torisaki M; Yamashita Y; Komatsu M; Tanahashi T; Ijichi K; Machida H
Graefes Arch Clin Exp Ophthalmol; 1994 Aug; 232(8):503-8. PubMed ID: 7926887
[TBL] [Abstract][Full Text] [Related]
4. Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys.
Soike K; Huang JL; Tu JI; Stouffer B; Mitroka JG; Swerdel M; Olsen S; Bonner DP; Tuomari AV; Field AK
J Infect Dis; 1992 Apr; 165(4):732-6. PubMed ID: 1313071
[TBL] [Abstract][Full Text] [Related]
5. Metabolic fate of [3H]1-beta-D-arabinofuranosyl-5-[(E)-2-bromovinyl]uracil in herpes simplex virus type 1-infected cells.
Ashida N; Sakata S; Machida H
Microbiol Immunol; 1997; 41(12):957-64. PubMed ID: 9492181
[TBL] [Abstract][Full Text] [Related]
6. Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2.
Suzutani T; Machida H; Sakuma T; Azuma M
Antimicrob Agents Chemother; 1988 Oct; 32(10):1547-51. PubMed ID: 2847634
[TBL] [Abstract][Full Text] [Related]
7. Manual and automated determination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and its metabolite (E)-5-(2-bromovinyl)uracil in urine.
Whigan DB; Schuster AE
J Chromatogr B Biomed Appl; 1995 Feb; 664(2):357-63. PubMed ID: 7780588
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Yokota T; Konno K; Mori S; Shigeta S; Kumagai M; Watanabe Y; Machida H
Mol Pharmacol; 1989 Aug; 36(2):312-6. PubMed ID: 2549386
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus.
Kawai H; Yoshida I; Suzutani T
Microbiol Immunol; 1993; 37(11):877-82. PubMed ID: 8295566
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds.
Machida H; Sakata S
Antiviral Res; 1984 Jun; 4(3):135-41. PubMed ID: 6089657
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication.
Lin JC; Machida H
Antimicrob Agents Chemother; 1988 Jul; 32(7):1068-72. PubMed ID: 2847639
[TBL] [Abstract][Full Text] [Related]
12. High-performance liquid chromatographic determination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and its metabolite (E)-5-(2-bromovinyl)uracil in serum.
Whigan DB; Cohen AI
J Chromatogr; 1991 Aug; 568(2):385-92. PubMed ID: 1783644
[TBL] [Abstract][Full Text] [Related]
13. Effect of BV-araU and acyclovir on varicella-zoster virus replication with various length and timing of drug exposure.
Machida H; Nishitani M; Ashida N
Microbiol Immunol; 1994; 38(2):109-15. PubMed ID: 8041297
[TBL] [Abstract][Full Text] [Related]
14. In vitro drug combination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil with anti-human immunodeficiency virus or anticancer nucleosides.
Machida H; Ashida N; Ikeda T; Sakata S; Baba M; Shigeta S
Antimicrob Agents Chemother; 1992 Jan; 36(1):214-6. PubMed ID: 1317147
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunoassay for hydroxyphosphinyl-3-hydroxybutanoic acid (SQ 33,600), a hypocholesterolemia agent.
Jagoda E; Stouffer B; Ogan M; Tsay HM; Turabi N; Mantha S; Yost F; Tu JI
Ther Drug Monit; 1993 Jun; 15(3):213-9. PubMed ID: 8333001
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo anti-herpes viral activities and biological properties of CV-araU.
Ashida N; Sakata S; Kano F; Nishitani M; Watanabe Y; Machida H
Antiviral Res; 1994 Dec; 25(3-4):179-84. PubMed ID: 7710267
[TBL] [Abstract][Full Text] [Related]
17. A specific radioimmunoassay for the measurement of gadoteridol, a contrast agent for magnetic resonance imaging in biological fluids.
Ogan MD; Reiss AC; Croze EM; Jagoda EM; Stouffer BC; Mantha S; Tsay HM; Yost FJ; Tu JI
J Pharm Sci; 1993 May; 82(5):475-9. PubMed ID: 8360824
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship between (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication.
Lin JC; Reefschläger J; Herrmann G; Pagano JS
Antiviral Res; 1992 Jan; 17(1):43-52. PubMed ID: 1310582
[TBL] [Abstract][Full Text] [Related]
19. Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Sakuma T
Antimicrob Agents Chemother; 1984 Jun; 25(6):742-6. PubMed ID: 6331298
[TBL] [Abstract][Full Text] [Related]
20. Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines.
Machida H; Ijichi K; Ohta A; Honda M; Niimura M
Microbiol Immunol; 1990; 34(11):959-65. PubMed ID: 1965323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
